Role of Platinums in Triple-Negative Breast Cancer

被引：24

作者：

Lynce, Filipa ^{[1
]}

Nunes, Raquel ^{[2
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, 450 Brookline Ave YC-1275, Boston, MA 02215 USA

[2] Sibley Mem Hosp, Johns Hopkins Sidney Kimmel Canc Ctr, Med Oncol, Bldg B,First Floor,5255 Loughboro Rd NW, Washington, DC 20016 USA

来源：

CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 05期

关键词：

Platinum; Carboplatin; Pathological complete response; Triple-negative breast cancer; Breast cancer; BRCA1; 2; carriers; Homologous recombination deficiency; Biomarkers; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; NEOADJUVANT CHEMOTHERAPY; STAGE-II; CARBOPLATIN; CISPLATIN; PLUS; VELIPARIB; TRIAL; CYCLOPHOSPHAMIDE;

D O I：

10.1007/s11912-021-01041-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewPlatinum compounds are used in the treatment of various types of cancer. Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of biomarkers in predicting response to platinum therapy.Recent FindingsAddition of carboplatin to a neoadjuvant chemotherapy regimen can result in improvement in the pathological complete response rates. The long-term benefit of the addition of carboplatin to standard chemotherapy regimens remains unproven. Single-agent platinum is an option in the treatment of advanced breast cancer. BRCA1/2 mutations predicted benefit from platinums in advanced, but not early stage breast cancer. There are yet no biomarkers to predict response to platinum in sporadic TNBC.SummaryPlatinum compounds are an option in the treatment of TNBC. Identification of biomarkers to select tumors most likely to derive benefit from these agents is still needed. Ongoing trials are exploring the role of platinum in the adjuvant setting and in combination with other agents, including immune checkpoint inhibitors.

引用

页数：7

共 38 条

[1]

Bardal S., 2011, APPL PHARM

[2] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].

Burstein, H. J. ;

Curigliano, G. ;

Loibl, S. ;

Dubsky, P. ;

Gnant, M. ;

Poortmans, P. ;

Colleoni, M. ;

Denkert, C. ;

Piccart-Gebhart, M. ;

Regan, M. ;

Senn, H. -J. ;

Winer, E. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557

[3] Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients [J].

Byrski, T. ;

Huzarski, T. ;

Dent, R. ;

Marczyk, E. ;

Jasiowka, M. ;

Gronwald, J. ;

Jakubowicz, J. ;

Cybulski, C. ;

Wisniowski, R. ;

Godlewski, D. ;

Lubinski, J. ;

Narod, S. A. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) :401-405

[4] EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].

CALVERT, AH ;

HARLAND, SJ ;

NEWELL, DR ;

SIDDIK, ZH ;

JONES, AC ;

MCELWAIN, TJ ;

RAJU, S ;

WILTSHAW, E ;

SMITH, IE ;

BAKER, JM ;

PECKHAM, MJ ;

HARRAP, KR .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147

[5] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[6] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].

Denkert, Carsten ;

von Minckwitz, Gunter ;

Brase, Jan C. ;

Sinn, Bruno V. ;

Gade, Stephan ;

Kronenwett, Ralf ;

Pfitzner, Berit M. ;

Salat, Christoph ;

Loi, Sherene ;

Schmitt, Wolfgang D. ;

Schem, Christian ;

Fisch, Karin ;

Darb-Esfahani, Silvia ;

Mehta, Keyur ;

Sotiriou, Christos ;

Wienert, Stephan ;

Klare, Peter ;

Andre, Fabrice ;

Klauschen, Frederick ;

Blohmer, Jens-Uwe ;

Krappmann, Kristin ;

Schmidt, Marcus ;

Tesch, Hans ;

Kuemmel, Sherko ;

Sinn, Peter ;

Jackisch, Christian ;

Dietel, Manfred ;

Reimer, Toralf ;

Untch, Michael ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991

[7] Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification [J].

Echavarria, Isabel ;

Lopez-Tarruella, Sara ;

Picornell, Antoni ;

Angel Garcia-Saenz, Jose ;

Jerez, Yolanda ;

Hoadley, Katherine ;

Gomez, Henry L. ;

Moreno, Fernando ;

Del Monte-Millan, Maria ;

Marquez-Rodas, Ivan ;

Alvarez, Enrique ;

Ramos-Medina, Rocio ;

Gayarre, Javier ;

Massarrah, Tatiana ;

Ocana, Inmaculada ;

Cebollero, Maria ;

Fuentes, Hugo ;

Barnadas, Agusti ;

Isabel Ballesteros, Ana ;

Bohn, Uriel ;

Perou, Charles M. ;

Martin, Miguel .

CLINICAL CANCER RESEARCH, 2018, 24 (08) :1845-1852

[8]

Gianni L., 2019, SAN ANTONIO BREAST C

[9] Impact of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Surgical Results From CALGB 40603 (Alliance) [J].

Golshan, Mehra ;

Cirrincione, Constance T. ;

Sikov, William M. ;

Berry, Donald A. ;

Jasinski, Sara ;

Weisberg, Tracey F. ;

Somlo, George ;

Hudis, Clifford ;

Winer, Eric ;

Ollila, David W. .

ANNALS OF SURGERY, 2015, 262 (03) :434-439

[10] Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial [J].

Hahnen, Eric ;

Lederer, Bianca ;

Hauke, Jan ;

Loibl, Sibylle ;

Kroeber, Sandra ;

Schneeweiss, Andreas ;

Denkert, Carsten ;

Fasching, Peter A. ;

Blohmer, Jens U. ;

Jackisch, Christian ;

Paepke, Stefan ;

Gerber, Bernd ;

Kuemmel, Sherko ;

Schem, Christian ;

Neidhardt, Guido ;

Huober, Jens ;

Rhiem, Kerstin ;

Costa, Serban ;

Altmueller, Janine ;

Hanusch, Claus ;

Thiele, Holger ;

Mueller, Volkmar ;

Nuernberg, Peter ;

Karn, Thomas ;

Nekljudova, Valentina ;

Untch, Michael ;

von Minckwitz, Gunter ;

Schmutzler, Rita K. .

JAMA ONCOLOGY, 2017, 3 (10) :1378-1385

← 1 2 3 4 →